These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. A Commentary on a recent update of the ovarian cancer risk attributable to menopausal hormone therapy. Gompel A; Burger H Climacteric; 2015 Jun; 18(3):376-8. PubMed ID: 25812672 [TBL] [Abstract][Full Text] [Related]
27. The timing of estrogen therapy after ovariectomy--implications for neurocognitive function. Maki PM Nat Clin Pract Endocrinol Metab; 2008 Sep; 4(9):494-5. PubMed ID: 18648334 [No Abstract] [Full Text] [Related]
28. Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Women: US Preventive Services Task Force Recommendation Statement. ; Grossman DC; Curry SJ; Owens DK; Barry MJ; Davidson KW; Doubeni CA; Epling JW; Kemper AR; Krist AH; Kurth AE; Landefeld CS; Mangione CM; Phipps MG; Silverstein M; Simon MA; Tseng CW JAMA; 2017 Dec; 318(22):2224-2233. PubMed ID: 29234814 [TBL] [Abstract][Full Text] [Related]
29. Hormone replacement therapy and ovarian cancer risk--any news? Riman T Acta Obstet Gynecol Scand; 2007; 86(9):1032-4. PubMed ID: 17712640 [No Abstract] [Full Text] [Related]
32. Cognitive decline and dementia in women after menopause: Prevention strategies. Stefanowski B; Kucharski M; Szeliga A; Snopek M; Kostrzak A; Smolarczyk R; Maciejewska-Jeske M; Duszewska A; Niwczyk O; Drozd S; Englert-Golon M; Smolarczyk K; Meczekalski B Maturitas; 2023 Feb; 168():53-61. PubMed ID: 36493633 [TBL] [Abstract][Full Text] [Related]
33. Effects of estrogen replacement therapy on estrogen receptor expression and immunoregulatory cytokine secretion in surgically induced menopausal women. Xia X; Zhang S; Yu Y; Zhao N; Liu R; Liu K; Chen X J Reprod Immunol; 2009 Jul; 81(1):89-96. PubMed ID: 19497624 [TBL] [Abstract][Full Text] [Related]
34. [Hormone substitution therapy in menopause and risk of breast cancer]. Colin C Rev Fr Gynecol Obstet; 1991 Jan; 86(1):27-8. PubMed ID: 2068481 [TBL] [Abstract][Full Text] [Related]
35. Hysterectomy, bilateral oophorectomy, and breast cancer risk in a racially diverse prospective cohort study. Lovett SM; Sandler DP; O'Brien KM J Natl Cancer Inst; 2023 Jun; 115(6):662-670. PubMed ID: 36806439 [TBL] [Abstract][Full Text] [Related]
36. Comparison of oral estrogens and estrogens plus androgen on bone mineral density, menopausal symptoms, and lipid-lipoprotein profiles in surgical menopause. Watts NB; Notelovitz M; Timmons MC; Addison WA; Wiita B; Downey LJ Obstet Gynecol; 1995 Apr; 85(4):529-37. PubMed ID: 7898828 [TBL] [Abstract][Full Text] [Related]
37. Hysterectomy status, estrogen use and quality of life in older women: the Rancho Bernardo study. Kritz-Silverstein D; Von Muhlen DG; Ganiats TG; Barrett-Connor E Qual Life Res; 2004 Feb; 13(1):55-62. PubMed ID: 15058787 [TBL] [Abstract][Full Text] [Related]
38. Ovarian conservation versus bilateral oophorectomy at the time of hysterectomy for benign disease. Parker WH Menopause; 2014 Feb; 21(2):192-4. PubMed ID: 23880797 [TBL] [Abstract][Full Text] [Related]
39. Race, Menopausal Hormone Therapy, and Invasive Breast Cancer in the Carolina Breast Cancer Study. DeBono NL; Robinson WR; Lund JL; Tse CK; Moorman PG; Olshan AF; Troester MA J Womens Health (Larchmt); 2018 Mar; 27(3):377-386. PubMed ID: 28570827 [TBL] [Abstract][Full Text] [Related]